Antisense Oligonucleotides (ASOs) Products for Cancer
Antisense oligonucleotides (ASOs) have emerged as an exciting and promising strategy for cancer therapy. The antisense technology is based on the sequence-specific binding of an antisense oligonucleotide to target mRNA, resulting in the prevention of gene translation. Antisense therapeutics offers one approach to target genes that are associated with the pathogenesis of human cancers, especially those that are not amenable to small-molecule or antibody inhibition. Clinical studies have shown that the treatment with ASOs is safe and leads to target downregulation in tumor tissues.
As a recognized world leader biotechnology company, Creative Biolabs offers high-quality ASO products for cancer therapy. A variety of genes have been validated as molecular targets for antisense therapy, such as the key regulators of cell growth, apoptosis, angiogenesis, and metastasis that are associated with the malignant phenotype of cancer cells rather than with normal cell physiology. Our platform has developed abundant antisense products targeting the mRNA of Bcl-2, Protein kinase C (PKC), c-raf or Ha-ras, etc. In addition, we are also committed to developing other new potential targets for specific antisense treatment of cancer. Please feel free to contact us by e-mail for a quote and further discussion with our scientists.
Reference
- Gleave, M. and Monia, B. (2005). Antisense therapy for cancer. Nature Reviews Cancer. 5(6), pp.468-479.
